Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
120
Trial Sponsor
Clinical Trial Start Date
September 7, 2020
0Primary Completion Date
August 11, 2023
0Study Completion Date
August 11, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
IL-20
FT5160
Cyclophosphamide0
Avelumab0
Fludarabine0
Interventional Trial Phase
Phase 10
Official Name
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors0
Last Updated
September 21, 2023
0Allocation Type
NA0
Intervention Model
Sequential Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
